<DOC>
	<DOCNO>NCT00226278</DOCNO>
	<brief_summary>Patients suffer Major Depressive Disorder Psychotic feature receive change medication previous two week receive `` usual '' treatment antidepressant , antipsychotic and/or mood stabilizer adjunct therapy use ORG34517 . The patient hospitalize two week monitor medication progress return site periodic assessment .</brief_summary>
	<brief_title>Safety Study ORG 34517 Major Depression With Psychotic Features</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>provide voluntary write informed consent trial participation scope nature investigation explain , start trial related activity able speak , read , understand , respond question follow instruction English DSMIV severe depressive episode psychotic feature , diagnose MINI single recurrent episode score PANSS item `` Delusions '' AND/OR `` Hallucinatory behavior '' least 4 screen baseline PANSS Positive Scale score least 16 screen baseline total score least 18 teh HAMD 17 item scale Screening Baseline stable dose usual treatment consist antidepressant , antipsychotic , mood stabilizer combination three drug class 18 include 70 year age Screening must willing hospitalize least 11 day Screening onwards . psychiatric diagnosis except MDD lifetime psychiatric diagnosis Bipolar Disorder I , schizophrenia schizoaffective disorder significant risk commit suicide currently treat carbamazepine valproate currently treat midazolam treat electroconvulsive therapy current episode currently treat one antidepressant currently treat one antipsychotic currently treat one mood stabilizer usual treatment start discontinue two week randomization usual treatment dose change within week prior randomization clinically unstable uncontrollable renal , hepatic , respiratory , haematological , cardiovascular cerebrovascular disease would put patient risk safety bias assessment efficacy know hypersensitivity reaction glucocorticoid antagonist clinically significant abnormal laboratory data untreated uncompensated clinically significant endocrine disorder diagnosis alcohol and/or drug dependence confirm positive result drug screen test illicit drug except cannabis use hormone replacement therapy Screening require concomitant treatment corticosteroid subject diagnose Cushing disease woman childbearing potential without adequate contraception woman positive pregnancy test screen baseline breastfeed mother male subject current diagnosis prostrate hypertrophia past history symptom prostrate hypertrophia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>